Promoting bone health in children and adolescents following solid organ transplantation

被引:3
作者
Kusumi, Kirstin [1 ]
Shaikhkhalil, Ala [2 ]
Patel, Hiren P. [2 ]
Mahan, John D. [2 ]
机构
[1] Akron Childrens Hosp, NEOMED, Rootstown, OH USA
[2] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA
关键词
bisphosphonates; bone; calcium; magnesium; metabolic bone disease; phosphorous; physical activity; solid organ transplant; vitamin D; CHRONIC KIDNEY-DISEASE; GROWTH-HORMONE TREATMENT; CLINICAL-PRACTICE RECOMMENDATIONS; PEDIATRIC RENAL-TRANSPLANTATION; VITAMIN-D DEFICIENCY; MINERAL DENSITY; LIVER-TRANSPLANTATION; PARATHYROID-HORMONE; INDUCED OSTEOPOROSIS; BIOCHEMICAL MARKERS;
D O I
10.1111/petr.13940
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Solid organ transplantation in children and adolescents provides many benefits through improving critical organ function, including better growth, development, cardiovascular status, and quality of life. Unfortunately, bone status may be adversely affected even when overall status is improving, due to issues with pre-existing bone disease as well as medications and nutritional challenges inherent post-transplantation. For all children and adolescents, bone status entering adulthood is a critical determinant of bone health through adulthood. The overall health and bone status of transplant recipients benefits from attention to regular physical activity, good nutrition, adequate calcium, phosphorous, magnesium and vitamin D intake and avoidance/minimization of soda, extra sodium, and obesity. Many immunosuppressive agents, especially glucocorticoids, can adversely affect bone function and development. Minimizing exposure to "bone-toxic" medications is an important part of promoting bone health in children post-transplantation. Existing guidelines detail how regular monitoring of bone status and biochemical markers can help detect bone abnormalities early and facilitate valuable bone-directed interventions. Attention to calcium and vitamin D supplementation, as well as tapering and withdrawing glucocorticoids as early as possible after transplant, can provide best bone outcomes for these children. Dual-energy X-ray absorptiometry can be useful to detect abnormal bone mass and fracture risk in this population and newer bone assessment methods are being evaluated in children at risk for poor bone outcomes. Newer bone therapies being explored in adults with transplants, particularly bisphosphonates and the RANKL inhibitor denosumab, may offer promise for children with low bone mass post-transplantation.
引用
收藏
页数:21
相关论文
共 155 条
  • [1] Glucocorticoid-induced osteoporosis: 2019 concise clinical review
    Adami, G.
    Saag, K. G.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 (06) : 1145 - 1156
  • [2] Mycophenolate mofetil and its mechanisms of action
    Allison, AC
    Eugui, EM
    [J]. IMMUNOPHARMACOLOGY, 2000, 47 (2-3): : 85 - 118
  • [3] Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society
    Anastasilakis, Athanasios D.
    Tsourdi, Elena
    Makras, Polyzois
    Polyzos, Stergios A.
    Meier, Christian
    McCloskey, Eugene V.
    Pepe, Jessica
    Zillikens, M. Carola
    [J]. BONE, 2019, 127 : 401 - 418
  • [4] Andia DC, 2008, HISTOL HISTOPATHOL, V23, P1177, DOI 10.14670/HH-23.1177
  • [5] [Anonymous], 2004, US Health and Human Services, P437
  • [6] Bone Densitometry in Children and Adolescents
    Bachrach, Laura K.
    Gordon, Catherine M.
    [J]. PEDIATRICS, 2016, 138 (04)
  • [7] Risk of hip and renal fracture among dialysis transplant recipients
    Ball, AM
    Gillen, DL
    Sherrard, D
    Weiss, NS
    Emerson, SS
    Seliger, SL
    Kestenbaum, BR
    Stehman-Breen, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (23): : 3014 - 3018
  • [8] Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta
    Biggin, A.
    Munns, C. F.
    [J]. CURRENT OSTEOPOROSIS REPORTS, 2017, 15 (05): : 412 - 418
  • [9] Methods for measurement of pediatric bone
    Binkley, Teresa L.
    Berry, Ryan
    Specker, Bonny L.
    [J]. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2008, 9 (02) : 95 - 106
  • [10] Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects
    Bonadonna, S
    Burattin, A
    Nuzzo, M
    Bugari, G
    Rosei, EA
    Valle, D
    Iori, N
    Bilezikian, JP
    Veldhuis, JD
    Giustina, A
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (02) : 199 - 205